Zacks Research upgraded shares of AEON Biopharma (NASDAQ:AEON – Free Report) to a hold rating in a report published on Wednesday,Zacks.com reports.
AEON Biopharma Trading Down 4.5%
AEON stock opened at $0.72 on Wednesday. AEON Biopharma has a 12 month low of $0.53 and a 12 month high of $1.45. The company has a 50-day moving average price of $0.94 and a 200 day moving average price of $1.00. The stock has a market cap of $18.12 million, a PE ratio of 3.98 and a beta of 0.66.
Hedge Funds Weigh In On AEON Biopharma
A hedge fund recently raised its stake in AEON Biopharma stock. XTX Topco Ltd raised its stake in AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) by 251.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,852 shares of the company’s stock after buying an additional 40,690 shares during the period. XTX Topco Ltd owned about 0.48% of AEON Biopharma worth $63,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 22.78% of the stock is currently owned by institutional investors.
About AEON Biopharma
AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.
Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.
Featured Articles
- Five stocks we like better than AEON Biopharma
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
